UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 87 filers reported holding UROGEN PHARMA LTD in Q4 2019. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $94,000 | +9.3% | 4,829 | +1.5% | 0.00% | – |
| Q4 2020 | $86,000 | -61.3% | 4,758 | -58.7% | 0.00% | – |
| Q3 2020 | $222,000 | -24.5% | 11,512 | +2.1% | 0.00% | -100.0% |
| Q2 2020 | $294,000 | +182.7% | 11,274 | +93.9% | 0.00% | 0.0% |
| Q1 2020 | $104,000 | -44.4% | 5,814 | +3.5% | 0.00% | 0.0% |
| Q4 2019 | $187,000 | +34.5% | 5,616 | -3.7% | 0.00% | 0.0% |
| Q3 2019 | $139,000 | -33.5% | 5,832 | +0.3% | 0.00% | 0.0% |
| Q2 2019 | $209,000 | +26.7% | 5,813 | +30.1% | 0.00% | 0.0% |
| Q1 2019 | $165,000 | -12.2% | 4,468 | +2.4% | 0.00% | 0.0% |
| Q4 2018 | $188,000 | +16.0% | 4,364 | +27.6% | 0.00% | 0.0% |
| Q3 2018 | $162,000 | +1.2% | 3,420 | +6.1% | 0.00% | 0.0% |
| Q2 2018 | $160,000 | +6.7% | 3,224 | +6.5% | 0.00% | 0.0% |
| Q1 2018 | $150,000 | +42.9% | 3,026 | +7.2% | 0.00% | 0.0% |
| Q4 2017 | $105,000 | – | 2,824 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
| Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
| Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
| MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
| DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
| SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
| BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
| Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |